Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRB1 | P17538 | 2/20 | 0.57 |
| ▸ | SYK | P43405 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 2/20 | 0.50 |
| ▸ | CASP1 | P29466 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | KYNU | Q16719 | 1/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 3/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 2/20 | 0.47 |
| ▸ | CTSS | P25774 | 2/20 | 0.47 |
| ▸ | ELANE | P08246 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL79250 | 1.00 | CTRB1 (0.57) | CTRB1SYKATMCASP1ALDH1A1 | |
| SCHEMBL555192 | 1.00 | CTRB1 (0.57) | CTRB1SYKATMCASP1ALDH1A1 | |
| SCHEMBL10966776 | 0.93 | CTRB1 (0.61) | CTRB1SYKATMCASP1ALDH1A1 | |
| SCHEMBL7986494 | 0.89 | CTRB1 (0.54) | CTRB1SYKATMCASP1CTSK | |
| SCHEMBL10964840 | 0.89 | CTRB1 (0.57) | CTRB1SYKATMCASP1ALDH1A1 | |
| SCHEMBL14530318 | 0.89 | SYK (0.60) | CTRB1SYKATMCASP1ALDH1A1 | |
| SCHEMBL14531561 | 0.89 | SYK (0.60) | CTRB1SYKATMCASP1ALDH1A1 | |
| SCHEMBL10964829 | 0.89 | CTRB1 (0.57) | CTRB1SYKATMCASP1ALDH1A1 | |
| SCHEMBL28184491 | 0.89 | CTRB1 (0.68) | CTRB1SYKATMALDH1A1TRPM8 | |
| SCHEMBL7280375 | 0.89 | CTRB1 (0.68) | CTRB1SYKATMALDH1A1TRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111148743-B | Inhibition of ubiquitin-specific peptidase 30 | 福马治疗有限公司 | 2023-12-15 | — | — | CN | disclosed |
| EP-2601177-B1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ASTRAZENECA AB (SE) | 2017-10-18 | — | — | EP | disclosed |
| US-20160176906-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2016-06-23 | — | — | US | disclosed |
| US-9248140-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2016-02-02 | — | — | US | disclosed |
| US-20150328239-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2015-11-19 | — | — | US | disclosed |
| US-9018381-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2015-04-28 | — | — | US | disclosed |
| US-20130310344-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ASTRAZENECA AB (UK) | 2013-11-21 | — | — | US | disclosed |
| EP-2601177-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | AstraZeneca AB (SE) | 2013-06-12 | — | — | EP | disclosed |
| US-20120035134-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | US | disclosed |
| WO-2012017251-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | WO | disclosed |
| CN-102304064-A | Method for preparing intermediate of Sitagliptin | HENGDIAN GROUP JIAYUAN CHEMICAL INDUSTRY CO LTD | 2012-01-04 | — | — | CN | disclosed |
| US-20070219192-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-09-20 | — | — | US | disclosed |
| US-20070219192-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219192-A1 | Certain chemical entities, compositions, and methods | KIF5B, KIF2C, PLK1 | CTRB1 4217/4885SYK 4470/4885ATM 1110/4885 |
| US-20120035134-A1 | CHEMICAL COMPOUNDS | BCL2, BCL2L1, BAX | CTRB1 2752/4885SYK 2797/4885ATM 2721/4885 |
| US-20150328239-A1 | Chemical Compounds | BCL2, BCL2L1, BAX | CTRB1 2752/4885SYK 2797/4885ATM 2721/4885 |
| US-20160176906-A1 | Chemical Compounds | BCL2, BCL2L1, BAX | CTRB1 2752/4885SYK 2797/4885ATM 2721/4885 |
| US-20130310344-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | BCL2, BAX, BCLAF1 | CTRB1 1929/4885SYK 4274/4885ATM 1506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.